DREAMM-5 platform trial: belantamab mafodotin (GSK2857916; belamaf; BLENREP) in combination with five different novel agents in patients (Pts) with relapsed/ refractory multiple myeloma (RRMM)

Autores: Weisel, K.; Richardson, P. G.; Trudel, S.; Callander, N.; Nooka, A.; Song, K.; Uttervall, K.; Minnema, M. C.; Rodríguez Otero, Paula; Struemper, H.; Yeakey, A.; de Oca, M. R.; Smith, L. M.; Jackson, N.; Kaisermann, M.; Im, E.; Basile, F. G.; Ahlers, C. M.; Holkova, B.; Gupta, I.; Kremer, B. E.; Quach, H.